Tobacco Mosaic Virus as an intranasal vaccine platform against Pseudomonas infections
Official title: Tobacco Mosaic Virus as a mucosal delivery platform for an intranasal vaccine against Pseudomonas aeruginosa
Funded at New York Medical College · NIH-11365083 · Data updated 2026-11-12
A short, patient-friendly vaccine idea using a plant virus to help protect people at risk from Pseudomonas infections, especially in the lungs and after burns.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York Medical College NIH-funded |
| Lab location | 1 site (Valhalla, United States) |
| Project start | July 2, 2025 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $204,380 |
| NIH project number | 5R21AI190341-02 |
| Project ID | NIH-11365083 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include patients at high risk for Pseudomonas infections, such as burn patients and individuals with cystic fibrosis or chronic lung conditions.
✕Less likely to help
Patients without exposure or risk to Pseudomonas infections may not directly benefit from this vaccine strategy.
What this research studies
This project explores a nasal vaccine strategy using tobacco mosaic virus as a delivery platform to protect against Pseudomonas aeruginosa infections in high-risk settings like burns and cystic fibrosis. It aims to create a mucosal vaccine that sticks to the respiratory tract where Pseudomonas often causes infections. The work is in early-stage, focused on design and feasibility in relevant models to support future human studies. If successful, it could lead to improved protection where traditional injections may not reach effectively.
Why it matters
Potential benefit: If successful, the vaccine approach could reduce mucosal infections and improve outcomes for people at risk of Pseudomonas infections.
How similar studies have gone: Vaccine strategies targeting mucosal surfaces have shown promise in preclinical work, but this specific plant-virus platform is early-stage.
Where this research is happening
-
New York Medical College
Valhalla, United States Active
Researchers
- Principal investigator: Arnaboldi, Paul Michael — New York Medical College
- Study coordinator: Arnaboldi, Paul Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.